Literature DB >> 24296679

Rheumatoid arthritis: New EULAR guidelines for RA: a job well done.

Joel M Kremer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24296679     DOI： 10.1038/nrrheum.2013.188

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  8 in total

Review 1.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

2.  The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.

Authors:  Naomi B Klarenbeek; Melek Güler-Yüksel; Sjoerd M van der Kooij; K Huub Han; H Karel Ronday; Pit J S M Kerstens; Patrick E H Seys; Tom W J Huizinga; Ben A C Dijkmans; Cornelia F Allaart
Journal:  Ann Rheum Dis       Date:  2011-03-17       Impact factor: 19.103

3.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

Authors:  Hyon K Choi; Miguel A Hernán; John D Seeger; James M Robins; Frederick Wolfe
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

4.  Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

Authors:  Jeffrey D Greenberg; Joel M Kremer; Jeffrey R Curtis; Marc C Hochberg; George Reed; Peter Tsao; Michael E Farkouh; Adeel Nasir; Soko Setoguchi; Daniel H Solomon
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

Review 5.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

6.  Therapies for active rheumatoid arthritis after methotrexate failure.

Authors:  James R O'Dell; Ted R Mikuls; Thomas H Taylor; Vandana Ahluwalia; Mary Brophy; Stuart R Warren; Robert A Lew; Amy C Cannella; Gary Kunkel; Ciaran S Phibbs; Aslam H Anis; Sarah Leatherman; Edward Keystone
Journal:  N Engl J Med       Date:  2013-06-11       Impact factor: 91.245

7.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103

8.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-10-25       Impact factor: 19.103
  8 in total
  3 in total

Review 1.  Treat-to-target in spondyloarthritis: implications for clinical trial designs.

Authors:  James Cheng-Chung Wei
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

2.  Increased autophagy in fibroblast-like synoviocytes leads to immune enhancement potential in rheumatoid arthritis.

Authors:  Ru Yang; Yingzi Zhang; Lin Wang; Ji Hu; Jian Wen; Leixi Xue; Mei Tang; Zhichun Liu; Jinxiang Fu
Journal:  Oncotarget       Date:  2017-02-28

3.  Hypoxia‑induced autophagy is inhibited by PADI4 knockdown, which promotes apoptosis of fibroblast‑like synoviocytes in rheumatoid arthritis.

Authors:  Tingting Fan; Changsong Zhang; Ming Zong; Lieying Fan
Journal:  Mol Med Rep       Date:  2018-01-26       Impact factor: 2.952
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.